HER-2 expression and cell proliferation: Prognostic markers in patients with node-negative breast cancer

Annalisa Volpi, Oriana Nanni, Franca De Paola, Anna Maria Granato, Annita Mangia, Franco Monti, Francesco Schittulli, Mario De Lena, Emanuela Scarpi, Paola Rosetti, Manlio Monti, Lorenzo Gianni, Dino Amadori, Angela Paradiso

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [3H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40% for patients with highly (≥30%) positive tumors and 26% for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.

Original languageEnglish
Pages (from-to)2708-2712
Number of pages5
JournalJournal of Clinical Oncology
Volume21
Issue number14
DOIs
Publication statusPublished - Jul 15 2003

Fingerprint

Cell Proliferation
Breast Neoplasms
Recurrence
Neoplasms
Quality Control
Thymidine
Immunohistochemistry
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

HER-2 expression and cell proliferation : Prognostic markers in patients with node-negative breast cancer. / Volpi, Annalisa; Nanni, Oriana; De Paola, Franca; Granato, Anna Maria; Mangia, Annita; Monti, Franco; Schittulli, Francesco; De Lena, Mario; Scarpi, Emanuela; Rosetti, Paola; Monti, Manlio; Gianni, Lorenzo; Amadori, Dino; Paradiso, Angela.

In: Journal of Clinical Oncology, Vol. 21, No. 14, 15.07.2003, p. 2708-2712.

Research output: Contribution to journalArticle

Volpi, Annalisa ; Nanni, Oriana ; De Paola, Franca ; Granato, Anna Maria ; Mangia, Annita ; Monti, Franco ; Schittulli, Francesco ; De Lena, Mario ; Scarpi, Emanuela ; Rosetti, Paola ; Monti, Manlio ; Gianni, Lorenzo ; Amadori, Dino ; Paradiso, Angela. / HER-2 expression and cell proliferation : Prognostic markers in patients with node-negative breast cancer. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 14. pp. 2708-2712.
@article{4736a065b41d491b9362ddc52f9853d4,
title = "HER-2 expression and cell proliferation: Prognostic markers in patients with node-negative breast cancer",
abstract = "Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [3H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40{\%} for patients with highly (≥30{\%}) positive tumors and 26{\%} for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.",
author = "Annalisa Volpi and Oriana Nanni and {De Paola}, Franca and Granato, {Anna Maria} and Annita Mangia and Franco Monti and Francesco Schittulli and {De Lena}, Mario and Emanuela Scarpi and Paola Rosetti and Manlio Monti and Lorenzo Gianni and Dino Amadori and Angela Paradiso",
year = "2003",
month = "7",
day = "15",
doi = "10.1200/JCO.2003.04.008",
language = "English",
volume = "21",
pages = "2708--2712",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "14",

}

TY - JOUR

T1 - HER-2 expression and cell proliferation

T2 - Prognostic markers in patients with node-negative breast cancer

AU - Volpi, Annalisa

AU - Nanni, Oriana

AU - De Paola, Franca

AU - Granato, Anna Maria

AU - Mangia, Annita

AU - Monti, Franco

AU - Schittulli, Francesco

AU - De Lena, Mario

AU - Scarpi, Emanuela

AU - Rosetti, Paola

AU - Monti, Manlio

AU - Gianni, Lorenzo

AU - Amadori, Dino

AU - Paradiso, Angela

PY - 2003/7/15

Y1 - 2003/7/15

N2 - Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [3H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40% for patients with highly (≥30%) positive tumors and 26% for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.

AB - Purpose: We analyzed the clinical relevance of HER-2 expression, widely investigated in breast cancer but with contradictory results, in the largest case series of node-negative breast cancer patients investigated to date. Patients and Methods: The pure prognostic value of HER-2 expression was investigated in 529 patients treated with locoregional therapy alone until early relapse. Proliferative activity was evaluated as [3H]thymidine labeling index and HER-2 expression by immunohistochemistry. All biologic determinations were conducted within the context of an intra- and interlaboratory National Quality Control Program. Results: HER-2 expression was not related to relapse-free survival in the overall series but was a significant discriminant of prognosis in the subgroup of patients with rapidly proliferating tumors. Six-year rate of relapse was 40% for patients with highly (≥30%) positive tumors and 26% for those with weakly HER-2-expressing tumors (P = .039). Conclusion: HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=0041629495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041629495&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.04.008

DO - 10.1200/JCO.2003.04.008

M3 - Article

C2 - 12860948

AN - SCOPUS:0041629495

VL - 21

SP - 2708

EP - 2712

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 14

ER -